---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-003483"
form_type: "8-K"
ticker: null
cik: "0001556263"
company_name: "Syros Pharmaceuticals, Inc."
filed_at: "2025-01-08T23:59:59+00:00"
generated_at: "2026-05-28T06:38:28.042707+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Syros receives Nasdaq deficiency notices for bid price, market value of listed securities, and publicly held shares

## Summary
- Bid price closed below $1.00 for 35 consecutive days; 180-day cure period until July 7, 2025.
- Minimum Value of Listed Securities (MVLS) below $50M for 30 consecutive business days.
- Market Value of Publicly Held Shares (MVPHS) below $15M for 35 consecutive business days.
- To regain compliance, stock must close at $1.00+ for 10 days; MVLS at $50M+; MVPHS at $15M+.
- May transfer to Nasdaq Capital Market or appeal delisting if non-compliance continues.

## SEC filing metadata
- accession: 0001193125-25-003483
- form_type: 8-K
- cik: 0001556263
- company_name: Syros Pharmaceuticals, Inc.
- filed_at: 2025-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1556263/000119312525003483/0001193125-25-003483-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1556263/000119312525003483/d854734d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-003483
- JSON: https://secwatch.observer/filing/0001193125-25-003483.json
- Plain text: https://secwatch.observer/filing/0001193125-25-003483.txt

## Key facts
- Listing & Compliance Notices
  Syros Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5450(b)(2)(A), 5450(b)(2)(C)
  source text: January 6, 2025, Syros Pharmaceuticals, Inc. (“ Syros ”) received deficiency letters (the “ Notices ”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“ Nasdaq ”) notifying Syros that: • for the last 35 consecutive business days, the bid price for Syros’ common stock has closed below $1.00 per share, which is the minimum bid price required to maintain continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “ Minimum Bid Requirement ”); • for the last 30 consecutive business days, the Minimum Value of Listed Securities, as defin
  evidence_url: https://www.sec.gov/Archives/edgar/data/1556263/000119312525003483/0001193125-25-003483-index.htm
- Listing & Compliance Notices
  Syros Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1)
  source text: January 6, 2025, Syros Pharmaceuticals, Inc. (“ Syros ”) received deficiency letters (the “ Notices ”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“ Nasdaq ”) notifying Syros that: • for the last 35 consecutive business days, the bid price for Syros’ common stock has closed below $1.00 per share, which is the minimum bid price required to maintain continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “ Minimum Bid Requirement ”); • for the last 30 consecutive business days, the Minimum Value of Listed Securities, as defin
  evidence_url: https://www.sec.gov/Archives/edgar/data/1556263/000119312525003483/0001193125-25-003483-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.